Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

November 9, 2023

Study Completion Date

March 31, 2025

Conditions

X-Linked Retinitis Pigmentosa

Interventions

BIOLOGICAL

rAAV2tYF-GRK1-RPGR

Adeno-associated virus vector expressing a human RPGR gene

Trial Locations (4)

Duke University, Durham

Cincinnati Eye Institute, Cincinnati

Retina Foundation of the Southwest, Dallas

Casey Eye Institute, Portland